Private plan not entered. Private-plan coverage, and how it coordinates with public programs, is not determined here; the Ontario public-program lines on this page remain conditional on the entered details and the program rules.
Paroxetine HCL
12 general benefit · 12 not a benefit
Apo-Paroxetine · DIN 02240908 · 20 mg · tablet
General benefitMarketed · checked October 5, 2026
StatusGeneral benefit
Write on scriptno code needed
Patient paysNot calculated: no patient details entered. Add age and coverage above to see what this patient would pay.
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)1 brand, same coverage
Apo-Paroxetine · DIN 02240908
Manufacturer: Apotex Inc.; listing date 2004-04-06
Health Canada: Marketed since 2003-10-24 · brand APO-PAROXETINE · ATC N06AB05 PAROXETINE · form Tablet · route Oral · ingredients PAROXETINE (PAROXETINE HYDROCHLORIDE) 20 MG · company Apotex inc · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product recordApo-Paroxetine: Formulary list price $0.33 per unit (the source does not state the unit; exact figure $0.3250). What the ministry pays, not the patient.
Ministry pays: $0.3250 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02240908)
Source record
DIN 02240908: Apo-Paroxetine
Raw flags: sec3=Y
Item: 281604078; group id 467; item number 1176; lccId None; manufacturer id APX
Source form: Tab; strength: 20mg
Recorded listing: General benefit
Source prices (unrounded): $0.3250; ministry $0.3250
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02240908
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=64499
Interchangeable products
AG-Paroxetine · DIN 02475545 · $0.3250
Auro-Paroxetine · DIN 02383284 · $0.3250
Bio-Paroxetine · DIN 02444917 · $0.3250
Co Paroxetine · DIN 02262754 · $0.3250
Jamp Paroxetine Tablets · DIN 02507781 · $0.3250
Jamp-Paroxetine · DIN 02368870 · $0.3250
M-Paroxetine · DIN 02467410 · $0.3250
Mar-Paroxetine · DIN 02411954 · $0.3250
Mint-Paroxetine · DIN 02421380 · $0.3250
NRA-Paroxetine · DIN 02479761 · $0.3250
PMS-Paroxetine · DIN 02247751 · $0.3250
Paroxetine · DIN 02282852 · $0.3250
Paroxetine · DIN 02388235 · $0.3250
Paxil · DIN 01940481 · $0.3250
Sandoz Paroxetine Tablets · DIN 02431785 · $0.3250
Teva-Paroxetine · DIN 02248557 · $0.3250
Shortage status: resolved shortage (ended April 23, 2021); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02240908
Shortage record checked October 6, 2026
Auro-Paroxetine · DIN 02383284 · 20 mg · tablet
General benefitMarketed · checked October 5, 2026
StatusGeneral benefit
Write on scriptno code needed
Patient paysNot calculated: no patient details entered. Add age and coverage above to see what this patient would pay.
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)1 brand, same coverage
Auro-Paroxetine · DIN 02383284
Manufacturer: Auro Pharma Inc.; listing date 2012-09-28
Health Canada: Marketed since 2012-07-24 · brand AURO-PAROXETINE · ATC N06AB05 PAROXETINE · form Tablet · route Oral · ingredients PAROXETINE (PAROXETINE HYDROCHLORIDE HEMIHYDRATE) 20 MG · company Auro pharma inc · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product recordAuro-Paroxetine: Formulary list price $0.33 per unit (the source does not state the unit; exact figure $0.3250). What the ministry pays, not the patient.
Ministry pays: $0.3250 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02383284)
Source record
DIN 02383284: Auro-Paroxetine
Raw flags: sec3=Y
Item: 281604078; group id 467; item number 1176; lccId None; manufacturer id AUR
Source form: Tab; strength: 20mg
Recorded listing: General benefit
Source prices (unrounded): $0.3250; ministry $0.3250
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02383284
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=86904
Interchangeable products
AG-Paroxetine · DIN 02475545 · $0.3250
Apo-Paroxetine · DIN 02240908 · $0.3250
Bio-Paroxetine · DIN 02444917 · $0.3250
Co Paroxetine · DIN 02262754 · $0.3250
Jamp Paroxetine Tablets · DIN 02507781 · $0.3250
Jamp-Paroxetine · DIN 02368870 · $0.3250
M-Paroxetine · DIN 02467410 · $0.3250
Mar-Paroxetine · DIN 02411954 · $0.3250
Mint-Paroxetine · DIN 02421380 · $0.3250
NRA-Paroxetine · DIN 02479761 · $0.3250
PMS-Paroxetine · DIN 02247751 · $0.3250
Paroxetine · DIN 02282852 · $0.3250
Paroxetine · DIN 02388235 · $0.3250
Paxil · DIN 01940481 · $0.3250
Sandoz Paroxetine Tablets · DIN 02431785 · $0.3250
Teva-Paroxetine · DIN 02248557 · $0.3250
Shortage status: resolved shortage (ended December 2, 2024); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02383284
Shortage record checked October 6, 2026
Bio-Paroxetine · DIN 02444917 · 20 mg · tablet
General benefitMarketed · checked November 18, 2026
StatusGeneral benefit
Write on scriptno code needed
Patient paysNot calculated: no patient details entered. Add age and coverage above to see what this patient would pay.
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)1 brand, same coverage
Bio-Paroxetine · DIN 02444917
Manufacturer: Biomed Pharma; listing date 2026-09-29
Health Canada: Marketed since 2016-12-21 · brand BIO-PAROXETINE · ATC N06AB05 PAROXETINE · form Tablet · route Oral · ingredients PAROXETINE (PAROXETINE HYDROCHLORIDE HEMIHYDRATE) 20 MG · company Biomed pharma · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product recordBio-Paroxetine: Formulary list price $0.33 per unit (the source does not state the unit; exact figure $0.3250). What the ministry pays, not the patient.
Ministry pays: $0.3250 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02444917)
Source record
DIN 02444917: Bio-Paroxetine
Raw flags: sec3=Y
Item: 281604078; group id 467; item number 1176; lccId None; manufacturer id BMP
Source form: Tab; strength: 20mg
Recorded listing: General benefit
Source prices (unrounded): $0.3250; ministry $0.3250
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02444917
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=93014
Interchangeable products
AG-Paroxetine · DIN 02475545 · $0.3250
Apo-Paroxetine · DIN 02240908 · $0.3250
Auro-Paroxetine · DIN 02383284 · $0.3250
Co Paroxetine · DIN 02262754 · $0.3250
Jamp Paroxetine Tablets · DIN 02507781 · $0.3250
Jamp-Paroxetine · DIN 02368870 · $0.3250
M-Paroxetine · DIN 02467410 · $0.3250
Mar-Paroxetine · DIN 02411954 · $0.3250
Mint-Paroxetine · DIN 02421380 · $0.3250
NRA-Paroxetine · DIN 02479761 · $0.3250
PMS-Paroxetine · DIN 02247751 · $0.3250
Paroxetine · DIN 02282852 · $0.3250
Paroxetine · DIN 02388235 · $0.3250
Paxil · DIN 01940481 · $0.3250
Sandoz Paroxetine Tablets · DIN 02431785 · $0.3250
Teva-Paroxetine · DIN 02248557 · $0.3250
Shortage status: resolved shortage (ended March 26, 2020); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02444917
Shortage record checked October 6, 2026
Jamp Paroxetine Tablets · DIN 02507781 · 20 mg · tablet
General benefitMarketed · checked November 18, 2026
StatusGeneral benefit
Write on scriptno code needed
Patient paysNot calculated: no patient details entered. Add age and coverage above to see what this patient would pay.
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)1 brand, same coverage
Jamp Paroxetine Tablets · DIN 02507781
Manufacturer: Jamp Pharma Corporation; listing date 2022-02-28
Health Canada: Marketed since 2022-01-03 · brand JAMP PAROXETINE TABLETS · ATC N06AB05 PAROXETINE · form Tablet · route Oral · ingredients PAROXETINE (PAROXETINE HYDROCHLORIDE) 20 MG · company Jamp pharma corporation · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product recordJamp Paroxetine Tablets: Formulary list price $0.33 per unit (the source does not state the unit; exact figure $0.3250). What the ministry pays, not the patient.
Ministry pays: $0.3250 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02507781)
Source record
DIN 02507781: Jamp Paroxetine Tablets
Raw flags: sec3=Y
Item: 281604078; group id 467; item number 1176; lccId None; manufacturer id JPC
Source form: Tab; strength: 20mg
Recorded listing: General benefit
Source prices (unrounded): $0.3250; ministry $0.3250
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02507781
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=99718
Interchangeable products
AG-Paroxetine · DIN 02475545 · $0.3250
Apo-Paroxetine · DIN 02240908 · $0.3250
Auro-Paroxetine · DIN 02383284 · $0.3250
Bio-Paroxetine · DIN 02444917 · $0.3250
Co Paroxetine · DIN 02262754 · $0.3250
Jamp-Paroxetine · DIN 02368870 · $0.3250
M-Paroxetine · DIN 02467410 · $0.3250
Mar-Paroxetine · DIN 02411954 · $0.3250
Mint-Paroxetine · DIN 02421380 · $0.3250
NRA-Paroxetine · DIN 02479761 · $0.3250
PMS-Paroxetine · DIN 02247751 · $0.3250
Paroxetine · DIN 02282852 · $0.3250
Paroxetine · DIN 02388235 · $0.3250
Paxil · DIN 01940481 · $0.3250
Sandoz Paroxetine Tablets · DIN 02431785 · $0.3250
Teva-Paroxetine · DIN 02248557 · $0.3250
Shortage status: no shortage or discontinuation reported (checked October 6, 2026); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02507781
Shortage record checked October 6, 2026
M-Paroxetine · DIN 02467410 · 20 mg · tablet
General benefitMarketed · checked November 18, 2026
StatusGeneral benefit
Write on scriptno code needed
Patient paysNot calculated: no patient details entered. Add age and coverage above to see what this patient would pay.
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)1 brand, same coverage
M-Paroxetine · DIN 02467410
Manufacturer: Mantra Pharma Inc.; listing date 2021-10-29
Health Canada: Marketed since 2018-03-07 · brand M-PAROXETINE · ATC N06AB05 PAROXETINE · form Tablet · route Oral · ingredients PAROXETINE (PAROXETINE HYDROCHLORIDE HEMIHYDRATE) 20 MG · company Mantra pharma inc · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product recordM-Paroxetine: Formulary list price $0.33 per unit (the source does not state the unit; exact figure $0.3250). What the ministry pays, not the patient.
Ministry pays: $0.3250 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02467410)
Source record
DIN 02467410: M-Paroxetine
Raw flags: sec3=Y
Item: 281604078; group id 467; item number 1176; lccId None; manufacturer id MAT
Source form: Tab; strength: 20mg
Recorded listing: General benefit
Source prices (unrounded): $0.3250; ministry $0.3250
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02467410
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=95579
Interchangeable products
AG-Paroxetine · DIN 02475545 · $0.3250
Apo-Paroxetine · DIN 02240908 · $0.3250
Auro-Paroxetine · DIN 02383284 · $0.3250
Bio-Paroxetine · DIN 02444917 · $0.3250
Co Paroxetine · DIN 02262754 · $0.3250
Jamp Paroxetine Tablets · DIN 02507781 · $0.3250
Jamp-Paroxetine · DIN 02368870 · $0.3250
Mar-Paroxetine · DIN 02411954 · $0.3250
Mint-Paroxetine · DIN 02421380 · $0.3250
NRA-Paroxetine · DIN 02479761 · $0.3250
PMS-Paroxetine · DIN 02247751 · $0.3250
Paroxetine · DIN 02282852 · $0.3250
Paroxetine · DIN 02388235 · $0.3250
Paxil · DIN 01940481 · $0.3250
Sandoz Paroxetine Tablets · DIN 02431785 · $0.3250
Teva-Paroxetine · DIN 02248557 · $0.3250
Shortage status: no shortage or discontinuation reported (checked October 6, 2026); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02467410
Shortage record checked October 6, 2026
Mar-Paroxetine · DIN 02411954 · 20 mg · tablet
General benefitMarketed · checked October 5, 2026
StatusGeneral benefit
Write on scriptno code needed
Patient paysNot calculated: no patient details entered. Add age and coverage above to see what this patient would pay.
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)1 brand, same coverage
Mar-Paroxetine · DIN 02411954
Manufacturer: Marcan Pharmaceuticals Inc.; listing date 2014-01-03
Health Canada: Marketed since 2014-06-24 · brand MAR-PAROXETINE · ATC N06AB05 PAROXETINE · form Tablet · route Oral · ingredients PAROXETINE (PAROXETINE HYDROCHLORIDE HEMIHYDRATE) 20 MG · company Marcan pharmaceuticals inc · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product recordMar-Paroxetine: Formulary list price $0.33 per unit (the source does not state the unit; exact figure $0.3250). What the ministry pays, not the patient.
Ministry pays: $0.3250 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02411954)
Source record
DIN 02411954: Mar-Paroxetine
Raw flags: sec3=Y
Item: 281604078; group id 467; item number 1176; lccId None; manufacturer id MAR
Source form: Tab; strength: 20mg
Recorded listing: General benefit
Source prices (unrounded): $0.3250; ministry $0.3250
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02411954
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=89652
Interchangeable products
AG-Paroxetine · DIN 02475545 · $0.3250
Apo-Paroxetine · DIN 02240908 · $0.3250
Auro-Paroxetine · DIN 02383284 · $0.3250
Bio-Paroxetine · DIN 02444917 · $0.3250
Co Paroxetine · DIN 02262754 · $0.3250
Jamp Paroxetine Tablets · DIN 02507781 · $0.3250
Jamp-Paroxetine · DIN 02368870 · $0.3250
M-Paroxetine · DIN 02467410 · $0.3250
Mint-Paroxetine · DIN 02421380 · $0.3250
NRA-Paroxetine · DIN 02479761 · $0.3250
PMS-Paroxetine · DIN 02247751 · $0.3250
Paroxetine · DIN 02282852 · $0.3250
Paroxetine · DIN 02388235 · $0.3250
Paxil · DIN 01940481 · $0.3250
Sandoz Paroxetine Tablets · DIN 02431785 · $0.3250
Teva-Paroxetine · DIN 02248557 · $0.3250
Shortage status: no shortage or discontinuation reported (checked October 6, 2026); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02411954
Shortage record checked October 6, 2026
Mint-Paroxetine · DIN 02421380 · 20 mg · tablet
General benefitMarketed · checked November 18, 2026
StatusGeneral benefit
Write on scriptno code needed
Patient paysNot calculated: no patient details entered. Add age and coverage above to see what this patient would pay.
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)1 brand, same coverage
Mint-Paroxetine · DIN 02421380
Manufacturer: Mint Pharmaceuticals Inc.; listing date 2014-05-29
Health Canada: Marketed since 2014-03-17 · brand MINT-PAROXETINE · ATC N06AB05 PAROXETINE · form Tablet · route Oral · ingredients PAROXETINE (PAROXETINE HYDROCHLORIDE HEMIHYDRATE) 20 MG · company Mint pharmaceuticals inc · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product recordMint-Paroxetine: Formulary list price $0.33 per unit (the source does not state the unit; exact figure $0.3250). What the ministry pays, not the patient.
Ministry pays: $0.3250 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02421380)
Source record
DIN 02421380: Mint-Paroxetine
Raw flags: sec3=Y
Item: 281604078; group id 467; item number 1176; lccId None; manufacturer id MIN
Source form: Tab; strength: 20mg
Recorded listing: General benefit
Source prices (unrounded): $0.3250; ministry $0.3250
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02421380
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=90601
Interchangeable products
AG-Paroxetine · DIN 02475545 · $0.3250
Apo-Paroxetine · DIN 02240908 · $0.3250
Auro-Paroxetine · DIN 02383284 · $0.3250
Bio-Paroxetine · DIN 02444917 · $0.3250
Co Paroxetine · DIN 02262754 · $0.3250
Jamp Paroxetine Tablets · DIN 02507781 · $0.3250
Jamp-Paroxetine · DIN 02368870 · $0.3250
M-Paroxetine · DIN 02467410 · $0.3250
Mar-Paroxetine · DIN 02411954 · $0.3250
NRA-Paroxetine · DIN 02479761 · $0.3250
PMS-Paroxetine · DIN 02247751 · $0.3250
Paroxetine · DIN 02282852 · $0.3250
Paroxetine · DIN 02388235 · $0.3250
Paxil · DIN 01940481 · $0.3250
Sandoz Paroxetine Tablets · DIN 02431785 · $0.3250
Teva-Paroxetine · DIN 02248557 · $0.3250
Shortage status: resolved shortage (ended March 2, 2018); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02421380
Shortage record checked October 6, 2026
NRA-Paroxetine · DIN 02479761 · 20 mg · tablet
General benefitMarketed · checked October 5, 2026
StatusGeneral benefit
Write on scriptno code needed
Patient paysNot calculated: no patient details entered. Add age and coverage above to see what this patient would pay.
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)1 brand, same coverage
NRA-Paroxetine · DIN 02479761
Manufacturer: Nora Pharma; listing date 2020-07-31
Health Canada: Marketed since 2018-12-10 · brand NRA-PAROXETINE · ATC N06AB05 PAROXETINE · form Tablet · route Oral · ingredients PAROXETINE (PAROXETINE HYDROCHLORIDE HEMIHYDRATE) 20 MG · company Nora pharma inc · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product recordNRA-Paroxetine: Formulary list price $0.33 per unit (the source does not state the unit; exact figure $0.3250). What the ministry pays, not the patient.
Ministry pays: $0.3250 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02479761)
Source record
DIN 02479761: NRA-Paroxetine
Raw flags: sec3=Y
Item: 281604078; group id 467; item number 1176; lccId None; manufacturer id NRA
Source form: Tab; strength: 20mg
Recorded listing: General benefit
Source prices (unrounded): $0.3250; ministry $0.3250
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02479761
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=97011
Interchangeable products
AG-Paroxetine · DIN 02475545 · $0.3250
Apo-Paroxetine · DIN 02240908 · $0.3250
Auro-Paroxetine · DIN 02383284 · $0.3250
Bio-Paroxetine · DIN 02444917 · $0.3250
Co Paroxetine · DIN 02262754 · $0.3250
Jamp Paroxetine Tablets · DIN 02507781 · $0.3250
Jamp-Paroxetine · DIN 02368870 · $0.3250
M-Paroxetine · DIN 02467410 · $0.3250
Mar-Paroxetine · DIN 02411954 · $0.3250
Mint-Paroxetine · DIN 02421380 · $0.3250
PMS-Paroxetine · DIN 02247751 · $0.3250
Paroxetine · DIN 02282852 · $0.3250
Paroxetine · DIN 02388235 · $0.3250
Paxil · DIN 01940481 · $0.3250
Sandoz Paroxetine Tablets · DIN 02431785 · $0.3250
Teva-Paroxetine · DIN 02248557 · $0.3250
Shortage status: no shortage or discontinuation reported (checked October 6, 2026); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02479761
Shortage record checked October 6, 2026
PMS-Paroxetine · DIN 02247751 · 20 mg · tablet
General benefitMarketed · checked October 5, 2026
StatusGeneral benefit
Write on scriptno code needed
Patient paysNot calculated: no patient details entered. Add age and coverage above to see what this patient would pay.
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)1 brand, same coverage
PMS-Paroxetine · DIN 02247751
Manufacturer: Pharmascience Inc.; listing date 2004-04-06
Health Canada: Marketed since 2003-10-29 · brand PMS-PAROXETINE · ATC N06AB05 PAROXETINE · form Tablet · route Oral · ingredients PAROXETINE (PAROXETINE HYDROCHLORIDE) 20 MG · company Pharmascience inc · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product recordPMS-Paroxetine: Formulary list price $0.33 per unit (the source does not state the unit; exact figure $0.3250). What the ministry pays, not the patient.
Ministry pays: $0.3250 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02247751)
Source record
DIN 02247751: PMS-Paroxetine
Raw flags: sec3=Y
Item: 281604078; group id 467; item number 1176; lccId None; manufacturer id PMS
Source form: Tab; strength: 20mg
Recorded listing: General benefit
Source prices (unrounded): $0.3250; ministry $0.3250
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02247751
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=72043
Interchangeable products
AG-Paroxetine · DIN 02475545 · $0.3250
Apo-Paroxetine · DIN 02240908 · $0.3250
Auro-Paroxetine · DIN 02383284 · $0.3250
Bio-Paroxetine · DIN 02444917 · $0.3250
Co Paroxetine · DIN 02262754 · $0.3250
Jamp Paroxetine Tablets · DIN 02507781 · $0.3250
Jamp-Paroxetine · DIN 02368870 · $0.3250
M-Paroxetine · DIN 02467410 · $0.3250
Mar-Paroxetine · DIN 02411954 · $0.3250
Mint-Paroxetine · DIN 02421380 · $0.3250
NRA-Paroxetine · DIN 02479761 · $0.3250
Paroxetine · DIN 02282852 · $0.3250
Paroxetine · DIN 02388235 · $0.3250
Paxil · DIN 01940481 · $0.3250
Sandoz Paroxetine Tablets · DIN 02431785 · $0.3250
Teva-Paroxetine · DIN 02248557 · $0.3250
Shortage status: resolved shortage (ended February 1, 2024); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02247751
Shortage record checked October 6, 2026
Paroxetine · DIN 02282852 · 20 mg · tablet
General benefitMarketed · checked October 5, 2026
StatusGeneral benefit
Write on scriptno code needed
Patient paysNot calculated: no patient details entered. Add age and coverage above to see what this patient would pay.
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)1 brand, same coverage
Paroxetine · DIN 02282852
Manufacturer: Sanis Health Inc.; listing date 2011-08-04
Health Canada: Marketed since 2021-09-27 · brand PAROXETINE · ATC N06AB05 PAROXETINE · form Tablet · route Oral · ingredients PAROXETINE (PAROXETINE HYDROCHLORIDE HEMIHYDRATE) 20 MG · company Sanis health inc · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product recordParoxetine: Formulary list price $0.33 per unit (the source does not state the unit; exact figure $0.3250). What the ministry pays, not the patient.
Ministry pays: $0.3250 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02282852)
Source record
DIN 02282852: Paroxetine
Raw flags: sec3=Y
Item: 281604078; group id 467; item number 1176; lccId None; manufacturer id SAI
Source form: Tab; strength: 20mg
Recorded listing: General benefit
Source prices (unrounded): $0.3250; ministry $0.3250
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02282852
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=76847
Interchangeable products
AG-Paroxetine · DIN 02475545 · $0.3250
Apo-Paroxetine · DIN 02240908 · $0.3250
Auro-Paroxetine · DIN 02383284 · $0.3250
Bio-Paroxetine · DIN 02444917 · $0.3250
Co Paroxetine · DIN 02262754 · $0.3250
Jamp Paroxetine Tablets · DIN 02507781 · $0.3250
Jamp-Paroxetine · DIN 02368870 · $0.3250
M-Paroxetine · DIN 02467410 · $0.3250
Mar-Paroxetine · DIN 02411954 · $0.3250
Mint-Paroxetine · DIN 02421380 · $0.3250
NRA-Paroxetine · DIN 02479761 · $0.3250
PMS-Paroxetine · DIN 02247751 · $0.3250
Paroxetine · DIN 02388235 · $0.3250
Paxil · DIN 01940481 · $0.3250
Sandoz Paroxetine Tablets · DIN 02431785 · $0.3250
Teva-Paroxetine · DIN 02248557 · $0.3250
Shortage status: resolved shortage (ended September 24, 2021); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02282852
Shortage record checked October 6, 2026
Paroxetine · DIN 02388235 · 20 mg · tablet
General benefitMarketed · checked October 5, 2026
StatusGeneral benefit
Write on scriptno code needed
Patient paysNot calculated: no patient details entered. Add age and coverage above to see what this patient would pay.
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)1 brand, same coverage
Paroxetine · DIN 02388235
Manufacturer: Sivem Pharmaceuticals ULC; listing date 2020-12-18
Health Canada: Marketed since 2016-02-09 · brand PAROXETINE · ATC N06AB05 PAROXETINE · form Tablet · route Oral · ingredients PAROXETINE (PAROXETINE HYDROCHLORIDE) 20 MG · company Sivem pharmaceuticals ulc · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product recordParoxetine: Formulary list price $0.33 per unit (the source does not state the unit; exact figure $0.3250). What the ministry pays, not the patient.
Ministry pays: $0.3250 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02388235)
Source record
DIN 02388235: Paroxetine
Raw flags: sec3=Y
Item: 281604078; group id 467; item number 1176; lccId None; manufacturer id SIV
Source form: Tab; strength: 20mg
Recorded listing: General benefit
Source prices (unrounded): $0.3250; ministry $0.3250
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02388235
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=87378
Interchangeable products
AG-Paroxetine · DIN 02475545 · $0.3250
Apo-Paroxetine · DIN 02240908 · $0.3250
Auro-Paroxetine · DIN 02383284 · $0.3250
Bio-Paroxetine · DIN 02444917 · $0.3250
Co Paroxetine · DIN 02262754 · $0.3250
Jamp Paroxetine Tablets · DIN 02507781 · $0.3250
Jamp-Paroxetine · DIN 02368870 · $0.3250
M-Paroxetine · DIN 02467410 · $0.3250
Mar-Paroxetine · DIN 02411954 · $0.3250
Mint-Paroxetine · DIN 02421380 · $0.3250
NRA-Paroxetine · DIN 02479761 · $0.3250
PMS-Paroxetine · DIN 02247751 · $0.3250
Paroxetine · DIN 02282852 · $0.3250
Paxil · DIN 01940481 · $0.3250
Sandoz Paroxetine Tablets · DIN 02431785 · $0.3250
Teva-Paroxetine · DIN 02248557 · $0.3250
Shortage status: discontinued (July 19, 2019, reported by SIVEM PHARMACEUTICALS ULC); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02388235
Shortage record checked October 6, 2026
Paxil · DIN 01940481 · 20 mg · tablet
General benefitMarketed · checked November 18, 2026
StatusGeneral benefit
Write on scriptno code needed
Patient paysNot calculated: no patient details entered. Add age and coverage above to see what this patient would pay.
Savings card: innoviCares lists Paxil (Ontario list dated 2026-09-10) — pays part of the brand-versus-generic difference after other coverage; free sign-up.
(innovicares.ca ↗)1 brand, same coverage
Paxil · DIN 01940481
Manufacturer: GlaxoSmithKline Inc., GlaxoSmithKline Consumer Health Care; listing date 1996-10-01
Health Canada: Marketed since 2002-09-13 · brand PAXIL TAB 20MG · ATC N06AB05 PAROXETINE · form Tablet · route Oral · ingredients PAROXETINE (PAROXETINE HYDROCHLORIDE) 20 MG · company Glaxosmithkline inc · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product recordMinistry pays: $0.3250 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 01940481)
Source record
DIN 01940481: Paxil
Raw flags: sec3=Y
Item: 281604078; group id 467; item number 1176; lccId None; manufacturer id GSK
Source form: Tab; strength: 20mg
Recorded listing: General benefit
Source prices (unrounded): $2.5496; ministry $0.3250
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=01940481
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=14007
Interchangeable products
AG-Paroxetine · DIN 02475545 · $0.3250
Apo-Paroxetine · DIN 02240908 · $0.3250
Auro-Paroxetine · DIN 02383284 · $0.3250
Bio-Paroxetine · DIN 02444917 · $0.3250
Co Paroxetine · DIN 02262754 · $0.3250
Jamp Paroxetine Tablets · DIN 02507781 · $0.3250
Jamp-Paroxetine · DIN 02368870 · $0.3250
M-Paroxetine · DIN 02467410 · $0.3250
Mar-Paroxetine · DIN 02411954 · $0.3250
Mint-Paroxetine · DIN 02421380 · $0.3250
NRA-Paroxetine · DIN 02479761 · $0.3250
PMS-Paroxetine · DIN 02247751 · $0.3250
Paroxetine · DIN 02282852 · $0.3250
Paroxetine · DIN 02388235 · $0.3250
Sandoz Paroxetine Tablets · DIN 02431785 · $0.3250
Teva-Paroxetine · DIN 02248557 · $0.3250
Shortage status: active shortage (reported April 30, 2026, estimated to end December 18, 2026, last updated June 23, 2026); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=01940481
Shortage record checked October 6, 2026
Apo-Paroxetine · DIN 02240907 · 10 mg · tablet
Off-Formulary Interchangeable, not an ODB benefitMarketed · checked November 18, 2026
StatusOff-Formulary Interchangeable, not an ODB benefit
Write on scriptnot a benefit; no Exceptional Access criteria on record (an EAP request with clinical rationale is still possible); see alternatives
Patient paysNot calculated: no patient details entered. Add age and coverage above to see what this patient would pay.
1 brand, same coverage
Apo-Paroxetine · DIN 02240907
Manufacturer: Apotex Inc.; listing date 2007-06-06
Health Canada: Marketed since 2003-10-24 · brand APO-PAROXETINE · ATC N06AB05 PAROXETINE · form Tablet · route Oral · ingredients PAROXETINE (PAROXETINE HYDROCHLORIDE) 10 MG · company Apotex inc · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product recordFormulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02240907)
Source record
DIN 02240907: Apo-Paroxetine
Raw flags: notABenefit=Y, sec3=Y, sec3b=Y
Item: 281604094; group id 467; item number 1175; lccId None; manufacturer id APX
Source form: Tab; strength: 10mg
Recorded listing: Off-Formulary Interchangeable, not an ODB benefit
Source prices (unrounded): $1.0430; ministry not recorded
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02240907
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=64498
Interchangeable products
AG-Paroxetine · DIN 02475537 · not recorded
Auro-Paroxetine · DIN 02383276 · not recorded
Bio-Paroxetine · DIN 02444909 · not recorded
Co Paroxetine · DIN 02262746 · not recorded
Jamp Paroxetine Tablets · DIN 02507773 · not recorded
Jamp-Paroxetine · DIN 02368862 · not recorded
M-Paroxetine · DIN 02467402 · not recorded
Mar-Paroxetine · DIN 02411946 · not recorded
Mint-Paroxetine · DIN 02421372 · not recorded
NRA-Paroxetine · DIN 02479753 · not recorded
PMS-Paroxetine · DIN 02247750 · not recorded
Paroxetine · DIN 02282844 · not recorded
Paroxetine · DIN 02388227 · not recorded
Paxil · DIN 02027887 · not recorded
Sandoz Paroxetine Tablets · DIN 02431777 · not recorded
Teva-Paroxetine · DIN 02248556 · not recorded
Shortage status: resolved shortage (ended October 5, 2023); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02240907
Shortage record checked October 6, 2026
Auro-Paroxetine · DIN 02383276 · 10 mg · tablet
Off-Formulary Interchangeable, not an ODB benefitMarketed · checked November 18, 2026
StatusOff-Formulary Interchangeable, not an ODB benefit
Write on scriptnot a benefit; no Exceptional Access criteria on record (an EAP request with clinical rationale is still possible); see alternatives
Patient paysNot calculated: no patient details entered. Add age and coverage above to see what this patient would pay.
1 brand, same coverage
Auro-Paroxetine · DIN 02383276
Manufacturer: Auro Pharma Inc.; listing date 2012-12-21
Health Canada: Marketed since 2012-07-24 · brand AURO-PAROXETINE · ATC N06AB05 PAROXETINE · form Tablet · route Oral · ingredients PAROXETINE (PAROXETINE HYDROCHLORIDE HEMIHYDRATE) 10 MG · company Auro pharma inc · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product recordFormulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02383276)
Source record
DIN 02383276: Auro-Paroxetine
Raw flags: notABenefit=Y, sec3=Y, sec3b=Y
Item: 281604094; group id 467; item number 1175; lccId None; manufacturer id AUR
Source form: Tab; strength: 10mg
Recorded listing: Off-Formulary Interchangeable, not an ODB benefit
Source prices (unrounded): $1.0430; ministry not recorded
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02383276
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=86903
Interchangeable products
AG-Paroxetine · DIN 02475537 · not recorded
Apo-Paroxetine · DIN 02240907 · not recorded
Bio-Paroxetine · DIN 02444909 · not recorded
Co Paroxetine · DIN 02262746 · not recorded
Jamp Paroxetine Tablets · DIN 02507773 · not recorded
Jamp-Paroxetine · DIN 02368862 · not recorded
M-Paroxetine · DIN 02467402 · not recorded
Mar-Paroxetine · DIN 02411946 · not recorded
Mint-Paroxetine · DIN 02421372 · not recorded
NRA-Paroxetine · DIN 02479753 · not recorded
PMS-Paroxetine · DIN 02247750 · not recorded
Paroxetine · DIN 02282844 · not recorded
Paroxetine · DIN 02388227 · not recorded
Paxil · DIN 02027887 · not recorded
Sandoz Paroxetine Tablets · DIN 02431777 · not recorded
Teva-Paroxetine · DIN 02248556 · not recorded
Shortage status: resolved shortage (ended October 28, 2022); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02383276
Shortage record checked October 6, 2026
Bio-Paroxetine · DIN 02444909 · 10 mg · tablet
Off-Formulary Interchangeable, not an ODB benefitMarketed · checked November 18, 2026
StatusOff-Formulary Interchangeable, not an ODB benefit
Write on scriptnot a benefit; no Exceptional Access criteria on record (an EAP request with clinical rationale is still possible); see alternatives
Patient paysNot calculated: no patient details entered. Add age and coverage above to see what this patient would pay.
1 brand, same coverage
Bio-Paroxetine · DIN 02444909
Manufacturer: Biomed Pharma; listing date 2026-09-29
Health Canada: Marketed since 2016-12-21 · brand BIO-PAROXETINE · ATC N06AB05 PAROXETINE · form Tablet · route Oral · ingredients PAROXETINE (PAROXETINE HYDROCHLORIDE HEMIHYDRATE) 10 MG · company Biomed pharma · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product recordFormulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02444909)
Source record
DIN 02444909: Bio-Paroxetine
Raw flags: notABenefit=Y, sec3=Y, sec3b=Y
Item: 281604094; group id 467; item number 1175; lccId None; manufacturer id BMP
Source form: Tab; strength: 10mg
Recorded listing: Off-Formulary Interchangeable, not an ODB benefit
Source prices (unrounded): $1.0430; ministry not recorded
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02444909
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=93013
Interchangeable products
AG-Paroxetine · DIN 02475537 · not recorded
Apo-Paroxetine · DIN 02240907 · not recorded
Auro-Paroxetine · DIN 02383276 · not recorded
Co Paroxetine · DIN 02262746 · not recorded
Jamp Paroxetine Tablets · DIN 02507773 · not recorded
Jamp-Paroxetine · DIN 02368862 · not recorded
M-Paroxetine · DIN 02467402 · not recorded
Mar-Paroxetine · DIN 02411946 · not recorded
Mint-Paroxetine · DIN 02421372 · not recorded
NRA-Paroxetine · DIN 02479753 · not recorded
PMS-Paroxetine · DIN 02247750 · not recorded
Paroxetine · DIN 02282844 · not recorded
Paroxetine · DIN 02388227 · not recorded
Paxil · DIN 02027887 · not recorded
Sandoz Paroxetine Tablets · DIN 02431777 · not recorded
Teva-Paroxetine · DIN 02248556 · not recorded
Shortage status: resolved shortage (ended August 8, 2018); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02444909
Shortage record checked October 6, 2026
Jamp Paroxetine Tablets · DIN 02507773 · 10 mg · tablet
Off-Formulary Interchangeable, not an ODB benefitMarketed · checked November 18, 2026
StatusOff-Formulary Interchangeable, not an ODB benefit
Write on scriptnot a benefit; no Exceptional Access criteria on record (an EAP request with clinical rationale is still possible); see alternatives
Patient paysNot calculated: no patient details entered. Add age and coverage above to see what this patient would pay.
1 brand, same coverage
Jamp Paroxetine Tablets · DIN 02507773
Manufacturer: Jamp Pharma Corporation; listing date 2021-07-30
Health Canada: Marketed since 2022-01-03 · brand JAMP PAROXETINE TABLETS · ATC N06AB05 PAROXETINE · form Tablet · route Oral · ingredients PAROXETINE (PAROXETINE HYDROCHLORIDE) 10 MG · company Jamp pharma corporation · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product recordFormulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02507773)
Source record
DIN 02507773: Jamp Paroxetine Tablets
Raw flags: notABenefit=Y, sec3=Y, sec3b=Y
Item: 281604094; group id 467; item number 1175; lccId None; manufacturer id JPC
Source form: Tab; strength: 10mg
Recorded listing: Off-Formulary Interchangeable, not an ODB benefit
Source prices (unrounded): $1.0430; ministry not recorded
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02507773
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=99717
Interchangeable products
AG-Paroxetine · DIN 02475537 · not recorded
Apo-Paroxetine · DIN 02240907 · not recorded
Auro-Paroxetine · DIN 02383276 · not recorded
Bio-Paroxetine · DIN 02444909 · not recorded
Co Paroxetine · DIN 02262746 · not recorded
Jamp-Paroxetine · DIN 02368862 · not recorded
M-Paroxetine · DIN 02467402 · not recorded
Mar-Paroxetine · DIN 02411946 · not recorded
Mint-Paroxetine · DIN 02421372 · not recorded
NRA-Paroxetine · DIN 02479753 · not recorded
PMS-Paroxetine · DIN 02247750 · not recorded
Paroxetine · DIN 02282844 · not recorded
Paroxetine · DIN 02388227 · not recorded
Paxil · DIN 02027887 · not recorded
Sandoz Paroxetine Tablets · DIN 02431777 · not recorded
Teva-Paroxetine · DIN 02248556 · not recorded
Shortage status: no shortage or discontinuation reported (checked October 6, 2026); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02507773
Shortage record checked October 6, 2026
M-Paroxetine · DIN 02467402 · 10 mg · tablet
Off-Formulary Interchangeable, not an ODB benefitMarketed · checked October 5, 2026
StatusOff-Formulary Interchangeable, not an ODB benefit
Write on scriptnot a benefit; no Exceptional Access criteria on record (an EAP request with clinical rationale is still possible); see alternatives
Patient paysNot calculated: no patient details entered. Add age and coverage above to see what this patient would pay.
1 brand, same coverage
M-Paroxetine · DIN 02467402
Manufacturer: Mantra Pharma Inc.; listing date 2021-11-30
Health Canada: Marketed since 2018-03-07 · brand M-PAROXETINE · ATC N06AB05 PAROXETINE · form Tablet · route Oral · ingredients PAROXETINE (PAROXETINE HYDROCHLORIDE HEMIHYDRATE) 10 MG · company Mantra pharma inc · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product recordFormulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02467402)
Source record
DIN 02467402: M-Paroxetine
Raw flags: notABenefit=Y, sec3=Y, sec3b=Y
Item: 281604094; group id 467; item number 1175; lccId None; manufacturer id MAT
Source form: Tab; strength: 10mg
Recorded listing: Off-Formulary Interchangeable, not an ODB benefit
Source prices (unrounded): $1.0430; ministry not recorded
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02467402
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=95578
Interchangeable products
AG-Paroxetine · DIN 02475537 · not recorded
Apo-Paroxetine · DIN 02240907 · not recorded
Auro-Paroxetine · DIN 02383276 · not recorded
Bio-Paroxetine · DIN 02444909 · not recorded
Co Paroxetine · DIN 02262746 · not recorded
Jamp Paroxetine Tablets · DIN 02507773 · not recorded
Jamp-Paroxetine · DIN 02368862 · not recorded
Mar-Paroxetine · DIN 02411946 · not recorded
Mint-Paroxetine · DIN 02421372 · not recorded
NRA-Paroxetine · DIN 02479753 · not recorded
PMS-Paroxetine · DIN 02247750 · not recorded
Paroxetine · DIN 02282844 · not recorded
Paroxetine · DIN 02388227 · not recorded
Paxil · DIN 02027887 · not recorded
Sandoz Paroxetine Tablets · DIN 02431777 · not recorded
Teva-Paroxetine · DIN 02248556 · not recorded
Shortage status: no shortage or discontinuation reported (checked October 6, 2026); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02467402
Shortage record checked October 6, 2026
Mar-Paroxetine · DIN 02411946 · 10 mg · tablet
Off-Formulary Interchangeable, not an ODB benefitMarketed · checked November 18, 2026
StatusOff-Formulary Interchangeable, not an ODB benefit
Write on scriptnot a benefit; no Exceptional Access criteria on record (an EAP request with clinical rationale is still possible); see alternatives
Patient paysNot calculated: no patient details entered. Add age and coverage above to see what this patient would pay.
1 brand, same coverage
Mar-Paroxetine · DIN 02411946
Manufacturer: Marcan Pharmaceuticals Inc.; listing date 2014-01-03
Health Canada: Marketed since 2014-06-24 · brand MAR-PAROXETINE · ATC N06AB05 PAROXETINE · form Tablet · route Oral · ingredients PAROXETINE (PAROXETINE HYDROCHLORIDE HEMIHYDRATE) 10 MG · company Marcan pharmaceuticals inc · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product recordFormulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02411946)
Source record
DIN 02411946: Mar-Paroxetine
Raw flags: notABenefit=Y, sec3=Y, sec3b=Y
Item: 281604094; group id 467; item number 1175; lccId None; manufacturer id MAR
Source form: Tab; strength: 10mg
Recorded listing: Off-Formulary Interchangeable, not an ODB benefit
Source prices (unrounded): $1.0430; ministry not recorded
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02411946
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=89654
Interchangeable products
AG-Paroxetine · DIN 02475537 · not recorded
Apo-Paroxetine · DIN 02240907 · not recorded
Auro-Paroxetine · DIN 02383276 · not recorded
Bio-Paroxetine · DIN 02444909 · not recorded
Co Paroxetine · DIN 02262746 · not recorded
Jamp Paroxetine Tablets · DIN 02507773 · not recorded
Jamp-Paroxetine · DIN 02368862 · not recorded
M-Paroxetine · DIN 02467402 · not recorded
Mint-Paroxetine · DIN 02421372 · not recorded
NRA-Paroxetine · DIN 02479753 · not recorded
PMS-Paroxetine · DIN 02247750 · not recorded
Paroxetine · DIN 02282844 · not recorded
Paroxetine · DIN 02388227 · not recorded
Paxil · DIN 02027887 · not recorded
Sandoz Paroxetine Tablets · DIN 02431777 · not recorded
Teva-Paroxetine · DIN 02248556 · not recorded
Shortage status: no shortage or discontinuation reported (checked October 6, 2026); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02411946
Shortage record checked October 6, 2026
Mint-Paroxetine · DIN 02421372 · 10 mg · tablet
Off-Formulary Interchangeable, not an ODB benefitMarketed · checked November 18, 2026
StatusOff-Formulary Interchangeable, not an ODB benefit
Write on scriptnot a benefit; no Exceptional Access criteria on record (an EAP request with clinical rationale is still possible); see alternatives
Patient paysNot calculated: no patient details entered. Add age and coverage above to see what this patient would pay.
1 brand, same coverage
Mint-Paroxetine · DIN 02421372
Manufacturer: Mint Pharmaceuticals Inc.; listing date 2014-05-29
Health Canada: Marketed since 2014-03-17 · brand MINT-PAROXETINE · ATC N06AB05 PAROXETINE · form Tablet · route Oral · ingredients PAROXETINE (PAROXETINE HYDROCHLORIDE HEMIHYDRATE) 10 MG · company Mint pharmaceuticals inc · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product recordFormulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02421372)
Source record
DIN 02421372: Mint-Paroxetine
Raw flags: notABenefit=Y, sec3=Y, sec3b=Y
Item: 281604094; group id 467; item number 1175; lccId None; manufacturer id MIN
Source form: Tab; strength: 10mg
Recorded listing: Off-Formulary Interchangeable, not an ODB benefit
Source prices (unrounded): $1.0430; ministry not recorded
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02421372
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=90600
Interchangeable products
AG-Paroxetine · DIN 02475537 · not recorded
Apo-Paroxetine · DIN 02240907 · not recorded
Auro-Paroxetine · DIN 02383276 · not recorded
Bio-Paroxetine · DIN 02444909 · not recorded
Co Paroxetine · DIN 02262746 · not recorded
Jamp Paroxetine Tablets · DIN 02507773 · not recorded
Jamp-Paroxetine · DIN 02368862 · not recorded
M-Paroxetine · DIN 02467402 · not recorded
Mar-Paroxetine · DIN 02411946 · not recorded
NRA-Paroxetine · DIN 02479753 · not recorded
PMS-Paroxetine · DIN 02247750 · not recorded
Paroxetine · DIN 02282844 · not recorded
Paroxetine · DIN 02388227 · not recorded
Paxil · DIN 02027887 · not recorded
Sandoz Paroxetine Tablets · DIN 02431777 · not recorded
Teva-Paroxetine · DIN 02248556 · not recorded
Shortage status: resolved shortage (ended April 5, 2018); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02421372
Shortage record checked October 6, 2026
NRA-Paroxetine · DIN 02479753 · 10 mg · tablet
Off-Formulary Interchangeable, not an ODB benefitMarketed · checked October 5, 2026
StatusOff-Formulary Interchangeable, not an ODB benefit
Write on scriptnot a benefit; no Exceptional Access criteria on record (an EAP request with clinical rationale is still possible); see alternatives
Patient paysNot calculated: no patient details entered. Add age and coverage above to see what this patient would pay.
1 brand, same coverage
NRA-Paroxetine · DIN 02479753
Manufacturer: Nora Pharma; listing date 2020-07-31
Health Canada: Marketed since 2018-12-10 · brand NRA-PAROXETINE · ATC N06AB05 PAROXETINE · form Tablet · route Oral · ingredients PAROXETINE (PAROXETINE HYDROCHLORIDE HEMIHYDRATE) 10 MG · company Nora pharma inc · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product recordFormulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02479753)
Source record
DIN 02479753: NRA-Paroxetine
Raw flags: notABenefit=Y, sec3=Y, sec3b=Y
Item: 281604094; group id 467; item number 1175; lccId None; manufacturer id NRA
Source form: Tab; strength: 10mg
Recorded listing: Off-Formulary Interchangeable, not an ODB benefit
Source prices (unrounded): $1.0430; ministry not recorded
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02479753
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=97010
Interchangeable products
AG-Paroxetine · DIN 02475537 · not recorded
Apo-Paroxetine · DIN 02240907 · not recorded
Auro-Paroxetine · DIN 02383276 · not recorded
Bio-Paroxetine · DIN 02444909 · not recorded
Co Paroxetine · DIN 02262746 · not recorded
Jamp Paroxetine Tablets · DIN 02507773 · not recorded
Jamp-Paroxetine · DIN 02368862 · not recorded
M-Paroxetine · DIN 02467402 · not recorded
Mar-Paroxetine · DIN 02411946 · not recorded
Mint-Paroxetine · DIN 02421372 · not recorded
PMS-Paroxetine · DIN 02247750 · not recorded
Paroxetine · DIN 02282844 · not recorded
Paroxetine · DIN 02388227 · not recorded
Paxil · DIN 02027887 · not recorded
Sandoz Paroxetine Tablets · DIN 02431777 · not recorded
Teva-Paroxetine · DIN 02248556 · not recorded
Shortage status: no shortage or discontinuation reported (checked October 6, 2026); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02479753
Shortage record checked October 6, 2026
PMS-Paroxetine · DIN 02247750 · 10 mg · tablet
Off-Formulary Interchangeable, not an ODB benefitMarketed · checked October 5, 2026
StatusOff-Formulary Interchangeable, not an ODB benefit
Write on scriptnot a benefit; no Exceptional Access criteria on record (an EAP request with clinical rationale is still possible); see alternatives
Patient paysNot calculated: no patient details entered. Add age and coverage above to see what this patient would pay.
1 brand, same coverage
PMS-Paroxetine · DIN 02247750
Manufacturer: Pharmascience Inc.; listing date 2007-06-06
Health Canada: Marketed since 2018-09-05 · brand PMS-PAROXETINE · ATC N06AB05 PAROXETINE · form Tablet · route Oral · ingredients PAROXETINE (PAROXETINE HYDROCHLORIDE) 10 MG · company Pharmascience inc · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product recordFormulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02247750)
Source record
DIN 02247750: PMS-Paroxetine
Raw flags: notABenefit=Y, sec3=Y, sec3b=Y
Item: 281604094; group id 467; item number 1175; lccId None; manufacturer id PMS
Source form: Tab; strength: 10mg
Recorded listing: Off-Formulary Interchangeable, not an ODB benefit
Source prices (unrounded): $1.0430; ministry not recorded
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02247750
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=72042
Interchangeable products
AG-Paroxetine · DIN 02475537 · not recorded
Apo-Paroxetine · DIN 02240907 · not recorded
Auro-Paroxetine · DIN 02383276 · not recorded
Bio-Paroxetine · DIN 02444909 · not recorded
Co Paroxetine · DIN 02262746 · not recorded
Jamp Paroxetine Tablets · DIN 02507773 · not recorded
Jamp-Paroxetine · DIN 02368862 · not recorded
M-Paroxetine · DIN 02467402 · not recorded
Mar-Paroxetine · DIN 02411946 · not recorded
Mint-Paroxetine · DIN 02421372 · not recorded
NRA-Paroxetine · DIN 02479753 · not recorded
Paroxetine · DIN 02282844 · not recorded
Paroxetine · DIN 02388227 · not recorded
Paxil · DIN 02027887 · not recorded
Sandoz Paroxetine Tablets · DIN 02431777 · not recorded
Teva-Paroxetine · DIN 02248556 · not recorded
Shortage status: resolved shortage (ended August 21, 2026); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02247750
Shortage record checked October 6, 2026
Paroxetine · DIN 02282844 · 10 mg · tablet
Off-Formulary Interchangeable, not an ODB benefitMarketed · checked October 5, 2026
StatusOff-Formulary Interchangeable, not an ODB benefit
Write on scriptnot a benefit; no Exceptional Access criteria on record (an EAP request with clinical rationale is still possible); see alternatives
Patient paysNot calculated: no patient details entered. Add age and coverage above to see what this patient would pay.
1 brand, same coverage
Paroxetine · DIN 02282844
Manufacturer: Sanis Health Inc.; listing date 2011-08-04
Health Canada: Marketed since 2021-09-27 · brand PAROXETINE · ATC N06AB05 PAROXETINE · form Tablet · route Oral · ingredients PAROXETINE (PAROXETINE HYDROCHLORIDE HEMIHYDRATE) 10 MG · company Sanis health inc · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product recordFormulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02282844)
Source record
DIN 02282844: Paroxetine
Raw flags: notABenefit=Y, sec3=Y, sec3b=Y
Item: 281604094; group id 467; item number 1175; lccId None; manufacturer id SAI
Source form: Tab; strength: 10mg
Recorded listing: Off-Formulary Interchangeable, not an ODB benefit
Source prices (unrounded): $1.0430; ministry not recorded
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02282844
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=76846
Interchangeable products
AG-Paroxetine · DIN 02475537 · not recorded
Apo-Paroxetine · DIN 02240907 · not recorded
Auro-Paroxetine · DIN 02383276 · not recorded
Bio-Paroxetine · DIN 02444909 · not recorded
Co Paroxetine · DIN 02262746 · not recorded
Jamp Paroxetine Tablets · DIN 02507773 · not recorded
Jamp-Paroxetine · DIN 02368862 · not recorded
M-Paroxetine · DIN 02467402 · not recorded
Mar-Paroxetine · DIN 02411946 · not recorded
Mint-Paroxetine · DIN 02421372 · not recorded
NRA-Paroxetine · DIN 02479753 · not recorded
PMS-Paroxetine · DIN 02247750 · not recorded
Paroxetine · DIN 02388227 · not recorded
Paxil · DIN 02027887 · not recorded
Sandoz Paroxetine Tablets · DIN 02431777 · not recorded
Teva-Paroxetine · DIN 02248556 · not recorded
Shortage status: resolved shortage (ended September 24, 2021); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02282844
Shortage record checked October 6, 2026
Paroxetine · DIN 02388227 · 10 mg · tablet
Off-Formulary Interchangeable, not an ODB benefitMarketed · checked October 5, 2026
StatusOff-Formulary Interchangeable, not an ODB benefit
Write on scriptnot a benefit; no Exceptional Access criteria on record (an EAP request with clinical rationale is still possible); see alternatives
Patient paysNot calculated: no patient details entered. Add age and coverage above to see what this patient would pay.
1 brand, same coverage
Paroxetine · DIN 02388227
Manufacturer: Sivem Pharmaceuticals ULC; listing date 2020-12-18
Health Canada: Marketed since 2016-02-09 · brand PAROXETINE · ATC N06AB05 PAROXETINE · form Tablet · route Oral · ingredients PAROXETINE (PAROXETINE HYDROCHLORIDE) 10 MG · company Sivem pharmaceuticals ulc · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product recordFormulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02388227)
Source record
DIN 02388227: Paroxetine
Raw flags: notABenefit=Y, sec3=Y, sec3b=Y
Item: 281604094; group id 467; item number 1175; lccId None; manufacturer id SIV
Source form: Tab; strength: 10mg
Recorded listing: Off-Formulary Interchangeable, not an ODB benefit
Source prices (unrounded): $1.0430; ministry not recorded
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02388227
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=87377
Interchangeable products
AG-Paroxetine · DIN 02475537 · not recorded
Apo-Paroxetine · DIN 02240907 · not recorded
Auro-Paroxetine · DIN 02383276 · not recorded
Bio-Paroxetine · DIN 02444909 · not recorded
Co Paroxetine · DIN 02262746 · not recorded
Jamp Paroxetine Tablets · DIN 02507773 · not recorded
Jamp-Paroxetine · DIN 02368862 · not recorded
M-Paroxetine · DIN 02467402 · not recorded
Mar-Paroxetine · DIN 02411946 · not recorded
Mint-Paroxetine · DIN 02421372 · not recorded
NRA-Paroxetine · DIN 02479753 · not recorded
PMS-Paroxetine · DIN 02247750 · not recorded
Paroxetine · DIN 02282844 · not recorded
Paxil · DIN 02027887 · not recorded
Sandoz Paroxetine Tablets · DIN 02431777 · not recorded
Teva-Paroxetine · DIN 02248556 · not recorded
Shortage status: no shortage or discontinuation reported (checked October 6, 2026); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02388227
Shortage record checked October 6, 2026
Teva-Paroxetine · DIN 02248556 · 10 mg · tablet
Off-Formulary Interchangeable, not an ODB benefitMarketed · checked November 18, 2026
StatusOff-Formulary Interchangeable, not an ODB benefit
Write on scriptnot a benefit; no Exceptional Access criteria on record (an EAP request with clinical rationale is still possible); see alternatives
Patient paysNot calculated: no patient details entered. Add age and coverage above to see what this patient would pay.
1 brand, same coverage
Teva-Paroxetine · DIN 02248556
Manufacturer: Teva Canada Limited; listing date 2007-06-06
Health Canada: Marketed since 2024-02-15 · brand TEVA-PAROXETINE · ATC N06AB05 PAROXETINE · form Tablet · route Oral · ingredients PAROXETINE (PAROXETINE HYDROCHLORIDE ACETONE SOLVATE) 10 MG · company Teva canada limited · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product recordFormulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02248556)
Source record
DIN 02248556: Teva-Paroxetine
Raw flags: notABenefit=Y, sec3=Y, sec3b=Y
Item: 281604094; group id 467; item number 1175; lccId None; manufacturer id TEV
Source form: Tab; strength: 10mg
Recorded listing: Off-Formulary Interchangeable, not an ODB benefit
Source prices (unrounded): $1.0430; ministry not recorded
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02248556
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=72911
Interchangeable products
AG-Paroxetine · DIN 02475537 · not recorded
Apo-Paroxetine · DIN 02240907 · not recorded
Auro-Paroxetine · DIN 02383276 · not recorded
Bio-Paroxetine · DIN 02444909 · not recorded
Co Paroxetine · DIN 02262746 · not recorded
Jamp Paroxetine Tablets · DIN 02507773 · not recorded
Jamp-Paroxetine · DIN 02368862 · not recorded
M-Paroxetine · DIN 02467402 · not recorded
Mar-Paroxetine · DIN 02411946 · not recorded
Mint-Paroxetine · DIN 02421372 · not recorded
NRA-Paroxetine · DIN 02479753 · not recorded
PMS-Paroxetine · DIN 02247750 · not recorded
Paroxetine · DIN 02282844 · not recorded
Paroxetine · DIN 02388227 · not recorded
Paxil · DIN 02027887 · not recorded
Sandoz Paroxetine Tablets · DIN 02431777 · not recorded
Shortage status: resolved shortage (ended June 16, 2026); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02248556
Shortage record checked October 6, 2026
Other products in the same Health Canada class (N06A, N06AB): coverage varies; not interchangeable
- Citalopram (Celexa): general benefit, not a benefit
- Escitalopram (Cipralex MELTZ): general benefit, not a benefit
- Fluoxetine (Prozac): general benefit, not a benefit
- Fluvoxamine (Luvox): general benefit
- Sertraline (Zoloft): general benefit
- Amitriptyline (Elavil): general benefit
17 more in the class list below
Other drugs in the same formulary class (28:16:04 Antidepressants) and how they are covered
Matched class: 28:16:04 Antidepressants
Drug-class inventory only. Lists recorded Ontario formulary products, not every Canadian medication; does not recommend treatment.
Covered without a code on the Ontario formulary: AMITRIPTYLINE, CLOMIPRAMINE HCL, FLUVOXAMINE MALEATE, NORTRIPTYLINE, PHENELZINE SULFATE, SERTRALINE HCL, TRANYLCYPROMINE SULFATE, VENLAFAXINE HCL, VORTIOXETINE HYDROBROMIDE
Some products covered without a code (check the product listing): CITALOPRAM HYDROBROMIDE, DESIPRAMINE, DOXEPIN HCL, DULOXETINE, ESCITALOPRAM, FLUOXETINE HCL, IMIPRAMINE, MIRTAZAPINE, MOCLOBEMIDE, TRAZODONE HYDROCHLORIDE, TRIMIPRAMINE
28:16:04 Antidepressants
· 51 products · Off-Formulary Interchangeable, not an ODB benefit (9), General benefit (42) · strengths: 10mg, 20mg, 40mg · Tab
· 40 products · Listed, not a benefit (2), General benefit (38) · strengths: 10mg, 20mg · Orally Disintegrating Tab, Orally Disintegrating Tablet, Tab
· 41 products · Off-Formulary Interchangeable, not an ODB benefit (17), Listed, not a benefit (2), General benefit (22) · strengths: 10mg, 20mg, 40mg, 60mg, 20mg/5mL · Cap, Oral Sol
· 6 products · General benefit · strengths: 50mg, 100mg · Tab
· 52 products · General benefit · strengths: 25mg, 50mg, 100mg · Cap
· 12 products · General benefit · strengths: 10mg, 25mg, 50mg · Tab
· 5 products · General benefit · strengths: 25mg, 50mg, 10mg · Tab
· 7 products · Listed, not a benefit (4), General benefit (3) · strengths: 25mg, 50mg, 75mg · Tab
· 20 products · General benefit (12), Off-Formulary Interchangeable, not an ODB benefit (8) · strengths: 10mg, 25mg, 50mg, 75mg, 100mg · Cap
· 40 products · Listed, not a benefit (2), General benefit (38) · strengths: 30mg, 60mg · DR Cap
· 9 products · Listed, not a benefit (3), General benefit (6) · strengths: 10mg, 25mg, 50mg · Tab
· 25 products · General benefit (16), Off-Formulary Interchangeable, not an ODB benefit (9) · strengths: 15mg, 30mg, 45mg · Orally Disintegrating Tab, Tab
Source: formulary-ed43-front-matter.txt Part V; ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=2026-09-22; class 28:16:04
and 12 more
Full class listing
Related classes: 28:08:04 Nonsteroidal Anti-Inflammatory Agents, 28:08:08 Opiate Agonists, 28:08:12 Opiate Partial Agonists, 28:08:92 Miscellaneous Analgesics and Antipyretics, 28:16:08 Tranquilizers, 28:16:12 Other Psychotropics, 28:36:08 Anticholinergic Agents, 28:36:20 Dopamine Receptor Agonists
Same formulary class, not same indication: class membership alone does not establish equivalent uses.